Morphic Therapeutic
Morphic Therapeutic, a biotech leader, pioneers oral integrin therapies using a unique discovery platform.
Founded
2015Morphic Therapeutic, a biotech leader, pioneers oral integrin therapies using a unique discovery platform.
Morphic Therapeutic was founded to revolutionize the treatment of various diseases through the development of oral integrin therapies. The company leverages a unique integrin discovery platform and decades of expertise to create a new generation of drugs. Their core mission is to transform treatment paradigms for patients suffering from autoimmune diseases, fibrosis, and cancer. Morphic's lead candidate, MORF-057, is a highly specific, orally-available inhibitor currently in Phase I trials for inflammatory bowel disease (IBD).
The company boasts affiliations with notable scientists and industry leaders, contributing to its innovative approach. Morphic has attracted significant investment from prominent venture capital firms, bolstering its research and development capabilities. Key achievements include advancing their lead candidate into clinical trials and developing a robust pipeline targeting both novel and validated integrin targets. Morphic Therapeutic's impact lies in its potential to offer more effective and convenient treatment options for patients with chronic and debilitating conditions.
Companies similar to Morphic Therapeutic include Pliant Therapeutics, VeraMorph, Forward Therapeutics and Morphoceuticals.
Morphic Therapeutic was founded in 2015.
Morphic Therapeutic's headquarters is located in Waltham, MA, US.
Morphic Therapeutic's most recent funding round was for $276M (USD) in May 2023.
As of May 3, 2023, Morphic Therapeutic has disclosed funding of $510.5M (USD). Undisclosed round amounts are excluded.
Morphic Therapeutic has 102 employees as of Feb 6, 2024.
Morphoceuticals
